Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.11, $0.03 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $42.8 million versus the consensus estimate of $42.03 million.

GUIDANCE:

Corcept Therapeutics sees FY2017 revenue of $157-162 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.